Evaluation of maternal and fetal outcomes in pregnant women with gestational thrombocytopenia

Basit Öğe Kaydı
dc.authoridSizer, Mulaim/0000-0003-4864-7287
dc.contributor.authorSunar, Nebahat
dc.contributor.authorSizer, Mulaim
dc.contributor.authorGunsel, Hamdin
dc.contributor.authorTekes, Guelten Cirkin
dc.contributor.authorDonmez, Dicle Akkilic
dc.contributor.authorIcen, Mehmet Sait
dc.date.accessioned2025-02-22T14:08:37Z
dc.date.available2025-02-22T14:08:37Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: Investigate the relationship between gestational thrombocytopenia (GT) and adverse maternal and fetal outcomes in pregnant women. Material and Methods: 97 patients who were diagnosed with gestational thrombocytopenia during pregnancy, had no other disease that causes thrombocytopenia and delivered in our clinic were included in the study. The patients were divided into two groups according to their platelet values. Group-1 platelet count was <70.000/mm3 and Group-2 platelet count was 70.000- 150.000/mm3. In the analysis of negative perinatal outcomes, logistic regression analysis was performed. P <0.05 was considered significant in the analysis results. Results: From the laboratory data of the patients diagnosed with gestational thrombocytopenia, the mean platelet count was 85.28 +/- 27.08 (min -max: 22-142) and mean hematocrit was 35.91 +/- 3.63 (min -max: 21-45). When the groups were evaluated considering their hematocrit values; the mean hematocrit value of the patients in Group-2 (36.42 +/- 3.22) was higher than the mean hematocrit value (34.26 +/- 4.39) of the patients in Group-1, and a significant difference was found between them (p:0.03). This significant difference was also present when the platelet value was taken as the limit of 110,000 (p:0.039). Discussion: Apgar scores are lower in patients diagnosed with gestational thrombocytopenia and with platelet values below 70,000, and the need for blood transfusion (erythrocyte suspension, FFP (Fresh Frozen Plasma) and platelet product) is higher. The need for erythrocyte transfusion continues even when the platelet limit is 80,000, and the need for platelet transfusion is 100,000.en_US
dc.identifier.doi10.4328/ACAM.22186
dc.identifier.endpage443en_US
dc.identifier.issn2667-663X
dc.identifier.issue6en_US
dc.identifier.startpage439en_US
dc.identifier.urihttps://doi.org/10.4328/ACAM.22186
dc.identifier.urihttps://hdl.handle.net/11468/29521
dc.identifier.volume15en_US
dc.identifier.wosWOS:001244769300014en_US
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherBayrakol Medical Publisheren_US
dc.relation.ispartofAnnals of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectGestational Thrombocytopeniaen_US
dc.subjectPregnancyen_US
dc.subjectAdverse Maternal and Fetal Outcomesen_US
dc.titleEvaluation of maternal and fetal outcomes in pregnant women with gestational thrombocytopeniaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu